Law360, New York (September 20, 2007, 12:00 AM ET) -- Actavis Group hf has struck back against a lawsuit filed by Sanofi-Aventis U.S. LLC alleging infringement of a patent for Eloxatin, saying it is not violating patents for the colon cancer drug.
Actavis and its subsidiaries filed an answer and counterclaims on Wednesday to Sanofi-Aventis’ lawsuit in the U.S. District Court for the District of New Jersey, denying charges that the Iceland-based generic drug maker has infringed on an Eloxatin patent through its abbreviated new drug application filed with the U.S. Food and Drug Administration....
Actavis Claims Cancer Drug Patents Are Invalid
To view the full article, take a free trial now.
